CA2989388A1 - Gene signatures predictive of metastatic disease - Google Patents
Gene signatures predictive of metastatic disease Download PDFInfo
- Publication number
- CA2989388A1 CA2989388A1 CA2989388A CA2989388A CA2989388A1 CA 2989388 A1 CA2989388 A1 CA 2989388A1 CA 2989388 A CA2989388 A CA 2989388A CA 2989388 A CA2989388 A CA 2989388A CA 2989388 A1 CA2989388 A1 CA 2989388A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- gene
- subject
- sample
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010061289 metastatic neoplasm Diseases 0.000 title claims abstract description 99
- 230000004547 gene signature Effects 0.000 title description 94
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 325
- 230000014509 gene expression Effects 0.000 claims abstract description 219
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 218
- 238000000034 method Methods 0.000 claims abstract description 171
- 201000011510 cancer Diseases 0.000 claims abstract description 154
- 238000004393 prognosis Methods 0.000 claims abstract description 80
- 238000012512 characterization method Methods 0.000 claims abstract description 52
- 239000000523 sample Substances 0.000 claims description 223
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 117
- 206010060862 Prostate cancer Diseases 0.000 claims description 113
- 206010006187 Breast cancer Diseases 0.000 claims description 75
- 208000026310 Breast neoplasm Diseases 0.000 claims description 75
- 230000001394 metastastic effect Effects 0.000 claims description 64
- 238000011282 treatment Methods 0.000 claims description 59
- 238000001574 biopsy Methods 0.000 claims description 51
- 238000010837 poor prognosis Methods 0.000 claims description 50
- 210000001519 tissue Anatomy 0.000 claims description 45
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 44
- 238000002271 resection Methods 0.000 claims description 44
- 230000003321 amplification Effects 0.000 claims description 43
- 206010027476 Metastases Diseases 0.000 claims description 35
- 238000001514 detection method Methods 0.000 claims description 32
- 238000012360 testing method Methods 0.000 claims description 32
- 238000003745 diagnosis Methods 0.000 claims description 31
- 238000001959 radiotherapy Methods 0.000 claims description 31
- 238000001356 surgical procedure Methods 0.000 claims description 30
- 230000009401 metastasis Effects 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 238000002493 microarray Methods 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 238000003860 storage Methods 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 229940127089 cytotoxic agent Drugs 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 102100029184 Calmodulin regulator protein PCP4 Human genes 0.000 claims description 13
- 101000988362 Homo sapiens Calmodulin regulator protein PCP4 Proteins 0.000 claims description 13
- 101000587539 Homo sapiens Metallothionein-1A Proteins 0.000 claims description 12
- 102100029698 Metallothionein-1A Human genes 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 239000002254 cytotoxic agent Substances 0.000 claims description 10
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 10
- 230000001419 dependent effect Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 238000004590 computer program Methods 0.000 claims description 9
- 230000003388 anti-hormonal effect Effects 0.000 claims description 8
- 238000004883 computer application Methods 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- 238000003559 RNA-seq method Methods 0.000 claims description 7
- 238000007781 pre-processing Methods 0.000 claims description 7
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 6
- 229940123237 Taxane Drugs 0.000 claims description 6
- 238000011065 in-situ storage Methods 0.000 claims description 6
- 239000002751 oligonucleotide probe Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 5
- 238000000636 Northern blotting Methods 0.000 claims description 5
- 229960000997 bicalutamide Drugs 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 229960000853 abiraterone Drugs 0.000 claims description 4
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 229960000714 sipuleucel-t Drugs 0.000 claims description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 3
- 239000002853 nucleic acid probe Substances 0.000 claims description 3
- 238000002626 targeted therapy Methods 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 238000011895 specific detection Methods 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 210000005267 prostate cell Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000002441 reversible effect Effects 0.000 description 119
- 101150094765 70 gene Proteins 0.000 description 99
- 238000003556 assay Methods 0.000 description 90
- 239000013615 primer Substances 0.000 description 80
- 238000004458 analytical method Methods 0.000 description 63
- 210000004027 cell Anatomy 0.000 description 63
- 102100038358 Prostate-specific antigen Human genes 0.000 description 57
- 210000002307 prostate Anatomy 0.000 description 49
- 230000004083 survival effect Effects 0.000 description 46
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 44
- 238000010200 validation analysis Methods 0.000 description 43
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 41
- 102100028163 ATP-binding cassette sub-family C member 4 Human genes 0.000 description 30
- 101000986629 Homo sapiens ATP-binding cassette sub-family C member 4 Proteins 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 29
- RZGZMLICFFEUIQ-UHFFFAOYSA-N 5-[(1-phenylcyclohexyl)amino]pentanoic acid Chemical compound C=1C=CC=CC=1C1(NCCCCC(=O)O)CCCCC1 RZGZMLICFFEUIQ-UHFFFAOYSA-N 0.000 description 27
- 101000734339 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Proteins 0.000 description 27
- 102100034825 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Human genes 0.000 description 27
- 239000000090 biomarker Substances 0.000 description 25
- 230000011987 methylation Effects 0.000 description 25
- 238000007069 methylation reaction Methods 0.000 description 25
- 230000027455 binding Effects 0.000 description 23
- 101000635965 Homo sapiens Myosin-binding protein C, slow-type Proteins 0.000 description 22
- 102100030735 Myosin-binding protein C, slow-type Human genes 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- 238000002790 cross-validation Methods 0.000 description 21
- 230000006870 function Effects 0.000 description 21
- 230000015654 memory Effects 0.000 description 21
- 238000012549 training Methods 0.000 description 21
- 239000000306 component Substances 0.000 description 20
- 230000000875 corresponding effect Effects 0.000 description 19
- 238000012545 processing Methods 0.000 description 19
- 101000632535 Homo sapiens SH3 domain-binding protein 4 Proteins 0.000 description 18
- 102100028409 SH3 domain-binding protein 4 Human genes 0.000 description 18
- 102000003610 TRPM8 Human genes 0.000 description 18
- 101150111302 Trpm8 gene Proteins 0.000 description 18
- 239000002299 complementary DNA Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 101001046554 Dictyostelium discoideum Thymidine kinase 1 Proteins 0.000 description 17
- 101000945477 Homo sapiens Thymidine kinase, cytosolic Proteins 0.000 description 17
- 108091033411 PCA3 Proteins 0.000 description 17
- 102100034838 Thymidine kinase, cytosolic Human genes 0.000 description 17
- 102100036526 Anoctamin-7 Human genes 0.000 description 16
- 101000928370 Homo sapiens Anoctamin-7 Proteins 0.000 description 16
- 230000005750 disease progression Effects 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 241000283707 Capra Species 0.000 description 15
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 15
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 15
- 101001008953 Homo sapiens Kinesin-like protein KIF11 Proteins 0.000 description 15
- 101001087372 Homo sapiens Securin Proteins 0.000 description 15
- 102100027629 Kinesin-like protein KIF11 Human genes 0.000 description 15
- 102100033004 Securin Human genes 0.000 description 15
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 102100030863 Eyes absent homolog 1 Human genes 0.000 description 14
- 101000938435 Homo sapiens Eyes absent homolog 1 Proteins 0.000 description 14
- 101000931462 Homo sapiens Protein FosB Proteins 0.000 description 14
- 102100020847 Protein FosB Human genes 0.000 description 14
- 239000002987 primer (paints) Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 102100040836 Claudin-1 Human genes 0.000 description 13
- 101000749331 Homo sapiens Claudin-1 Proteins 0.000 description 13
- 101000741900 Homo sapiens POTE ankyrin domain family member H Proteins 0.000 description 13
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 13
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 13
- 101000818517 Homo sapiens Zinc-alpha-2-glycoprotein Proteins 0.000 description 13
- 102100038758 POTE ankyrin domain family member H Human genes 0.000 description 13
- 238000011529 RT qPCR Methods 0.000 description 13
- 102100021144 Zinc-alpha-2-glycoprotein Human genes 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 238000000491 multivariate analysis Methods 0.000 description 13
- 101001125931 Arabidopsis thaliana Plastidial pyruvate kinase 2 Proteins 0.000 description 12
- 101000880402 Homo sapiens Metalloreductase STEAP4 Proteins 0.000 description 12
- 101001125939 Homo sapiens Plakophilin-1 Proteins 0.000 description 12
- 101000962469 Homo sapiens Transcription factor MafF Proteins 0.000 description 12
- 102100037654 Metalloreductase STEAP4 Human genes 0.000 description 12
- 102100029331 Plakophilin-1 Human genes 0.000 description 12
- 102100039187 Transcription factor MafF Human genes 0.000 description 12
- 230000008685 targeting Effects 0.000 description 12
- 102100030005 Calpain-6 Human genes 0.000 description 11
- 102100027088 Dual specificity protein phosphatase 5 Human genes 0.000 description 11
- 101000793671 Homo sapiens Calpain-6 Proteins 0.000 description 11
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 11
- 101000982010 Homo sapiens Myelin proteolipid protein Proteins 0.000 description 11
- 101001131830 Homo sapiens PDZ domain-containing RING finger protein 4 Proteins 0.000 description 11
- 101000891842 Homo sapiens Protein FAM3B Proteins 0.000 description 11
- 101000864743 Homo sapiens Secreted frizzled-related protein 1 Proteins 0.000 description 11
- 101001129124 Mannheimia haemolytica Outer membrane lipoprotein 1 Proteins 0.000 description 11
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 11
- 101000761187 Odontomachus monticola U-poneritoxin(01)-Om1a Proteins 0.000 description 11
- 102100034575 PDZ domain-containing RING finger protein 4 Human genes 0.000 description 11
- 102100040307 Protein FAM3B Human genes 0.000 description 11
- 102100030058 Secreted frizzled-related protein 1 Human genes 0.000 description 11
- 102000008847 Serpin Human genes 0.000 description 11
- 108050000761 Serpin Proteins 0.000 description 11
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000003908 quality control method Methods 0.000 description 11
- 239000003001 serine protease inhibitor Substances 0.000 description 11
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 10
- 102100032522 Cyclin-dependent kinases regulatory subunit 2 Human genes 0.000 description 10
- 101000942317 Homo sapiens Cyclin-dependent kinases regulatory subunit 2 Proteins 0.000 description 10
- 101000947695 Homo sapiens Microfibrillar-associated protein 5 Proteins 0.000 description 10
- 101001129132 Homo sapiens Perilipin-1 Proteins 0.000 description 10
- 101001000368 Homo sapiens Proline, histidine and glycine-rich protein 1 Proteins 0.000 description 10
- 101000825949 Homo sapiens R-spondin-2 Proteins 0.000 description 10
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 description 10
- 101000739754 Homo sapiens Semenogelin-1 Proteins 0.000 description 10
- 101000891352 Homo sapiens Transcription elongation factor A protein-like 7 Proteins 0.000 description 10
- 101000787286 Homo sapiens Valine-tRNA ligase Proteins 0.000 description 10
- 101000787276 Homo sapiens Valine-tRNA ligase, mitochondrial Proteins 0.000 description 10
- 102100036203 Microfibrillar-associated protein 5 Human genes 0.000 description 10
- 102100031261 Perilipin-1 Human genes 0.000 description 10
- 102100035871 Proline, histidine and glycine-rich protein 1 Human genes 0.000 description 10
- 102100022763 R-spondin-2 Human genes 0.000 description 10
- 102100022766 R-spondin-3 Human genes 0.000 description 10
- 102100037550 Semenogelin-1 Human genes 0.000 description 10
- 102100040419 Transcription elongation factor A protein-like 7 Human genes 0.000 description 10
- 102100025607 Valine-tRNA ligase Human genes 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 102100037437 Beta-defensin 1 Human genes 0.000 description 9
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 description 9
- 101001056473 Homo sapiens Keratin, type II cytoskeletal 5 Proteins 0.000 description 9
- 101000868472 Homo sapiens Sialoadhesin Proteins 0.000 description 9
- 101000795753 Homo sapiens mRNA decay activator protein ZFP36 Proteins 0.000 description 9
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 9
- 102100032855 Sialoadhesin Human genes 0.000 description 9
- 102100035804 Zinc finger protein 823 Human genes 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 102100025384 Acrosomal protein KIAA1210 Human genes 0.000 description 8
- 102100039181 Ankyrin repeat domain-containing protein 1 Human genes 0.000 description 8
- 102100021391 Cationic amino acid transporter 3 Human genes 0.000 description 8
- 206010061819 Disease recurrence Diseases 0.000 description 8
- 101000889396 Homo sapiens Ankyrin repeat domain-containing protein 1 Proteins 0.000 description 8
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 8
- 101000972278 Homo sapiens Mucin-6 Proteins 0.000 description 8
- 101000633617 Homo sapiens Thrombospondin-4 Proteins 0.000 description 8
- 101000655155 Homo sapiens Transmembrane protein 158 Proteins 0.000 description 8
- 101710060037 KIAA1210 Proteins 0.000 description 8
- 102100030417 Matrilysin Human genes 0.000 description 8
- 102100022493 Mucin-6 Human genes 0.000 description 8
- 108091006230 SLC7A3 Proteins 0.000 description 8
- 102100029219 Thrombospondin-4 Human genes 0.000 description 8
- 102100033036 Transmembrane protein 158 Human genes 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 238000011472 radical prostatectomy Methods 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 7
- 108091023037 Aptamer Proteins 0.000 description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 7
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 7
- 108091029430 CpG site Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102100023929 Heparan sulfate glucosamine 3-O-sulfotransferase 3A1 Human genes 0.000 description 7
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 7
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 7
- 101001048118 Homo sapiens Heparan sulfate glucosamine 3-O-sulfotransferase 3A1 Proteins 0.000 description 7
- 101001125858 Homo sapiens Peptidase inhibitor 15 Proteins 0.000 description 7
- 101000744882 Homo sapiens Zinc finger protein 185 Proteins 0.000 description 7
- 101000802394 Homo sapiens Zinc finger protein 765 Proteins 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 102100029323 Peptidase inhibitor 15 Human genes 0.000 description 7
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 7
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 7
- 102100040032 Zinc finger protein 185 Human genes 0.000 description 7
- 102100034990 Zinc finger protein 765 Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 102000017904 ADRA2C Human genes 0.000 description 6
- 101000720032 Homo sapiens Alpha-2C adrenergic receptor Proteins 0.000 description 6
- 101000594302 Homo sapiens Transcription termination factor 3, mitochondrial Proteins 0.000 description 6
- 101000626577 Homo sapiens Transmembrane protein 178A Proteins 0.000 description 6
- 102100035551 Transcription termination factor 3, mitochondrial Human genes 0.000 description 6
- 102100024892 Transmembrane protein 178A Human genes 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- -1 bisulphite ions Chemical class 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 108091047998 miR-578 stem-loop Proteins 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000007067 DNA methylation Effects 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 5
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 5
- 108091008611 Protein Kinase B Proteins 0.000 description 5
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 108091008053 gene clusters Proteins 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 108091069755 miR-4530 stem-loop Proteins 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 101150072531 10 gene Proteins 0.000 description 4
- 208000014061 Extranodal Extension Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 101000662690 Homo sapiens Trafficking protein particle complex subunit 10 Proteins 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 4
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 4
- 206010071019 Prostatic dysplasia Diseases 0.000 description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
- 102100037456 Trafficking protein particle complex subunit 10 Human genes 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 230000004049 epigenetic modification Effects 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000010801 machine learning Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000007481 next generation sequencing Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000007637 random forest analysis Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 4
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 102100032091 ALK and LTK ligand 2 Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 3
- 101000776351 Homo sapiens ALK and LTK ligand 2 Proteins 0.000 description 3
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 3
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 3
- 102000027545 TRPM Human genes 0.000 description 3
- 108091008847 TRPM Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000010230 functional analysis Methods 0.000 description 3
- 238000011223 gene expression profiling Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000000683 nonmetastatic effect Effects 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000001625 seminal vesicle Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 201000010653 vesiculitis Diseases 0.000 description 3
- 101150028074 2 gene Proteins 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 2
- 208000035346 Margins of Excision Diseases 0.000 description 2
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 2
- 108091062154 Mir-205 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 230000026279 RNA modification Effects 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 238000003070 Statistical process control Methods 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 238000003705 background correction Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000007475 c-index Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011498 curative surgery Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 2
- 238000002408 directed self-assembly Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 238000010209 gene set analysis Methods 0.000 description 2
- 238000007417 hierarchical cluster analysis Methods 0.000 description 2
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 230000006607 hypermethylation Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010249 in-situ analysis Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004886 process control Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 208000017497 prostate disease Diseases 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 238000000575 proteomic method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 description 1
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100022815 Alpha-2A adrenergic receptor Human genes 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000756842 Homo sapiens Alpha-2A adrenergic receptor Proteins 0.000 description 1
- 101001123334 Homo sapiens Proteoglycan 3 Proteins 0.000 description 1
- 101000983152 Homo sapiens Putative inactive group IIC secretory phospholipase A2 Proteins 0.000 description 1
- 101000616112 Homo sapiens Stress-associated endoplasmic reticulum protein 1 Proteins 0.000 description 1
- 101000747564 Homo sapiens UBX domain-containing protein 1 Proteins 0.000 description 1
- 101000939496 Homo sapiens UBX domain-containing protein 10 Proteins 0.000 description 1
- 101000818754 Homo sapiens Zinc finger protein 18 Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 101100028908 Lotus japonicus PCS3 gene Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 101150055260 MTERF1 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108700028031 Myelin Basic Proteins 0.000 description 1
- FOFDIMHVKGYHRU-UHFFFAOYSA-N N-(1,3-benzodioxol-5-ylmethyl)-4-(4-benzofuro[3,2-d]pyrimidinyl)-1-piperazinecarbothioamide Chemical compound C12=CC=CC=C2OC2=C1N=CN=C2N(CC1)CCN1C(=S)NCC1=CC=C(OCO2)C2=C1 FOFDIMHVKGYHRU-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102100026830 Putative inactive group IIC secretory phospholipase A2 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- BCZUAADEACICHN-UHFFFAOYSA-N SGX-523 Chemical compound C1=NN(C)C=C1C1=NN2C(SC=3C=C4C=CC=NC4=CC=3)=NN=C2C=C1 BCZUAADEACICHN-UHFFFAOYSA-N 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102100021813 Stress-associated endoplasmic reticulum protein 1 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100024950 Transcription termination factor 1, mitochondrial Human genes 0.000 description 1
- 102100040201 UBX domain-containing protein 1 Human genes 0.000 description 1
- 102100029646 UBX domain-containing protein 10 Human genes 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 101000962654 Vespa orientalis Mastoparan Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 238000001772 Wald test Methods 0.000 description 1
- 102100021377 Zinc finger protein 18 Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940002006 firmagon Drugs 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229950008692 foretinib Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229950002133 iniparib Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000007855 methylation-specific PCR Methods 0.000 description 1
- 108091087148 miR-20 stem-loop Proteins 0.000 description 1
- 108091066984 miR-20-1 stem-loop Proteins 0.000 description 1
- 108091076199 miR-20-2 stem-loop Proteins 0.000 description 1
- 108091059434 miR-45 stem-loop Proteins 0.000 description 1
- 108091029227 miR-45-1 stem-loop Proteins 0.000 description 1
- 108091085809 miR-45-2 stem-loop Proteins 0.000 description 1
- 108091060293 miR-453 stem-loop Proteins 0.000 description 1
- 108091033330 miR-57 stem-loop Proteins 0.000 description 1
- 108091023714 miR-57-1 stem-loop Proteins 0.000 description 1
- 108091082257 miR-57-2 stem-loop Proteins 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229950003968 motesanib Drugs 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 238000007838 multiplex ligation-dependent probe amplification Methods 0.000 description 1
- 238000010202 multivariate logistic regression analysis Methods 0.000 description 1
- 239000011807 nanoball Substances 0.000 description 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000010239 partial least squares discriminant analysis Methods 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012660 pharmacological inhibitor Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000039 preparative column chromatography Methods 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- APTZNLHMIGJTEW-UHFFFAOYSA-N pyraflufen-ethyl Chemical compound C1=C(Cl)C(OCC(=O)OCC)=CC(C=2C(=C(OC(F)F)N(C)N=2)Cl)=C1F APTZNLHMIGJTEW-UHFFFAOYSA-N 0.000 description 1
- 238000013442 quality metrics Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229960000160 recombinant therapeutic protein Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
- 229950004707 rucaparib Drugs 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- URLYINUFLXOMHP-HTVVRFAVSA-N tcn-p Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229950005976 tivantinib Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940097704 vantas Drugs 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
- 229950011257 veliparib Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1510684.2A GB201510684D0 (en) | 2015-06-17 | 2015-06-17 | Gene signatures predictive of metastatic disease |
| GB1510684.2 | 2015-06-17 | ||
| PCT/GB2016/051825 WO2016203262A2 (en) | 2015-06-17 | 2016-06-17 | Gene signatures predictive of metastatic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2989388A1 true CA2989388A1 (en) | 2016-12-22 |
Family
ID=53784091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2989388A Abandoned CA2989388A1 (en) | 2015-06-17 | 2016-06-17 | Gene signatures predictive of metastatic disease |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210254166A1 (enExample) |
| EP (1) | EP3310927B1 (enExample) |
| JP (1) | JP2018527886A (enExample) |
| CN (1) | CN108513587A (enExample) |
| CA (1) | CA2989388A1 (enExample) |
| GB (1) | GB201510684D0 (enExample) |
| HK (1) | HK1246367A1 (enExample) |
| WO (1) | WO2016203262A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11341138B2 (en) * | 2017-12-06 | 2022-05-24 | International Business Machines Corporation | Method and system for query performance prediction |
| GB201901439D0 (en) * | 2019-02-01 | 2019-03-27 | Univ London | Method of predicting survival rates for cancer patients |
| GB201903015D0 (en) * | 2019-03-08 | 2019-04-17 | Univ Edinburgh | Macrophage expression in breast cancer |
| GB201903014D0 (en) * | 2019-03-06 | 2019-04-17 | Univ Edinburgh | Macrophage markers in cancer |
| CA3168490A1 (en) * | 2020-01-21 | 2021-07-29 | Miha STAJDOHAR | Evaluating the robustness and transferability of predictive signatures across molecular biomarker datasets |
| EP4133491A1 (en) | 2020-04-09 | 2023-02-15 | Tempus Labs, Inc. | Predicting likelihood and site of metastasis from patient records |
| CN116096899A (zh) | 2020-06-29 | 2023-05-09 | Ionis制药公司 | 调节plp1的化合物和方法 |
| US20230390367A1 (en) * | 2020-10-19 | 2023-12-07 | Temple University - Of The Commonwealth System Of Higher Education | Genetic approach to suppress coronaviruses |
| CN120197220B (zh) * | 2025-05-23 | 2025-08-01 | 华信咨询设计研究院有限公司 | 一种基于数据集中度的数据风险评估方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4437975A (en) | 1977-07-20 | 1984-03-20 | Mobil Oil Corporation | Manufacture of lube base stock oil |
| CA1340843C (en) | 1987-07-31 | 1999-12-07 | J. Lawrence Burg | Selective amplification of target polynucleotide sequences |
| KR0148265B1 (ko) | 1988-12-16 | 1998-10-15 | 에프.지이.엠 헤르만스 | 자가-지속 서열 복제 시스템 |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| EP1474528A4 (en) * | 2000-10-13 | 2006-06-14 | Protein Design Labs Inc | METHODS FOR DIAGNOSING PROSTATE CANCER, COMPOSITIONS AND METHODS FOR SCREENING PROSTATE CANCER MODULATORS |
| WO2004067726A2 (en) | 2003-01-29 | 2004-08-12 | Keck Graduate Institute | Isothermal reactions for the amplification of oligonucleotides |
| EP1604014A4 (en) * | 2003-03-20 | 2008-03-26 | Dana Farber Cancer Inst Inc | GENE EXPRESSION IN BREAST CANCER |
| US7306910B2 (en) * | 2003-04-24 | 2007-12-11 | Veridex, Llc | Breast cancer prognostics |
| AU2005300688B2 (en) | 2004-11-03 | 2012-02-02 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
| US20140018249A1 (en) * | 2006-07-26 | 2014-01-16 | Health Discovery Corporation | Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia |
| JP2010535529A (ja) | 2007-08-13 | 2010-11-25 | アルマック ダイアグノスティックス リミテッド | マイクロアレイ製造用３’ベースシークエンシング手法 |
| WO2010068839A2 (en) * | 2008-12-11 | 2010-06-17 | The Regents Of The University Of California | Membrane compositions and methods for making and using them |
| CA2782620A1 (en) * | 2009-12-01 | 2011-06-09 | Compendia Bioscience, Inc. | Classification of cancers |
| EP2709614A4 (en) * | 2011-05-17 | 2015-04-15 | Takeda Pharmaceutical | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER |
| US20150218646A1 (en) * | 2012-07-20 | 2015-08-06 | Diagnocure Inc | Methods, kits and compositions for providing a clinical assessment of prostate cancer |
-
2015
- 2015-06-17 GB GBGB1510684.2A patent/GB201510684D0/en not_active Ceased
-
2016
- 2016-06-17 CA CA2989388A patent/CA2989388A1/en not_active Abandoned
- 2016-06-17 EP EP16731299.0A patent/EP3310927B1/en active Active
- 2016-06-17 WO PCT/GB2016/051825 patent/WO2016203262A2/en not_active Ceased
- 2016-06-17 JP JP2017565108A patent/JP2018527886A/ja active Pending
- 2016-06-17 CN CN201680045157.3A patent/CN108513587A/zh active Pending
- 2016-06-17 US US15/736,667 patent/US20210254166A1/en not_active Abandoned
- 2016-06-17 HK HK18105968.7A patent/HK1246367A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016203262A3 (en) | 2017-01-26 |
| EP3310927A2 (en) | 2018-04-25 |
| EP3310927B1 (en) | 2021-05-19 |
| CN108513587A (zh) | 2018-09-07 |
| JP2018527886A (ja) | 2018-09-27 |
| HK1246367A1 (zh) | 2018-09-07 |
| GB201510684D0 (en) | 2015-08-05 |
| US20210254166A1 (en) | 2021-08-19 |
| WO2016203262A2 (en) | 2016-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3310927B1 (en) | Gene signatures predictive of metastatic disease | |
| EP3080293B1 (en) | Prostate cancer classification | |
| Chen et al. | Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance | |
| AU2019250606B2 (en) | Improved classification and prognosis of prostate cancer | |
| CN117413072A (zh) | 用于通过核酸甲基化分析检测癌症的方法和系统 | |
| US20240002947A1 (en) | Method of predicting risk of recurrence of cancer | |
| JP2009528825A (ja) | デュークスｂ大腸がんの再発を予測するための分子的解析 | |
| US20090192045A1 (en) | Molecular staging of stage ii and iii colon cancer and prognosis | |
| WO2014165753A1 (en) | Methods and compositions for diagnosis of glioblastoma or a subtype thereof | |
| WO2016044330A1 (en) | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm | |
| Montalbo et al. | Prognostic value of circulating microRNAs in upper tract urinary carcinoma | |
| Hwang et al. | Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer | |
| Low et al. | A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer | |
| Ai et al. | The down-regulation of long non-coding RNA LINC01088 is associated with the poor prognosis of epithelial ovarian cancer patients | |
| WO2017046714A1 (en) | Methylation signature in squamous cell carcinoma of head and neck (hnscc) and applications thereof | |
| Goh et al. | Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer | |
| Cui et al. | MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone | |
| Zhang et al. | Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer | |
| EP2655663A2 (en) | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease | |
| Wang | YaXuan Wang, Jinfeng Wang, JiaXing He, Bo Ji, ZhongQi Pang, JianShe Wang, Yang Liu and MingHua Ren | |
| PaI-nková et al. | Research Article Cross-platform Data Analysis Reveals a Generic Gene Expression Signature for Microsatellite Instability in Colorectal Cancer | |
| WO2020104482A1 (en) | Methods for predicting metastatic potential in patients suffering from sdhb-mutated paraganglioma | |
| Montalbo Calafell et al. | Prognostic value of circulating microRNAs in upper tract urinary carcinoma | |
| Muthuvelan et al. | Identification of gene expression signature in estrogen receptor positive breast carcinoma | |
| KR20150002237A (ko) | 전립선암 진단용 바이오마커, 및 이를 포함하는 전립선암 진단용 키트 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220301 |